My main point was that some large pharma, or any large corporation for that matter, get a bit uneasy if there is not a lot of capital on the balance sheet. We are still a very small company. I remember a few years ago when we got the animal health business from Amgen. They were not allowed to PR it, and released it on an 8K two days after Christmas. To boot, our CEO was a relative, his son I believe, of the founder of Amgen! The dilution would be meaningless, at this point!
It would also be gobbled up by the Tutes.
News 
Market Data 
Discover 
